Physician profile

Monica M Wellemeyer

Physician Assistant · Wichita, KS

NPI 1093079394

$396.98

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$142.46

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Melinta Therapeutics, LLC $88.11 2022
Csl Behring $69.29 2022-2023 Hizentra
Astellas Pharma US INC $59.06 2023 Cresemba
Astrazeneca Pharmaceuticals LP $51.56 2022-2023 Evusheld
Takeda Pharmaceuticals U.S.A., INC. $36.56 2022-2023 Cuvitru
Abbvie INC. $28.29 2022
Mayne Pharma Commercial LLC $24.90 2022
Gilead Sciences, INC. $14.04 2023
Ferring Pharmaceuticals INC. $13.08 2022
Merck Sharp & Dohme LLC $12.09 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Monica M Wellemeyer

$396.98

in general payments reported 2019-2025

Years
2022-2023
Top company
Melinta Therapeutics, LLC

https://glasscript.com/doctor/10690118/monica-m-wellemeyer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.